Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 86

Results For "IDA"

1812 News Found

Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr
News | November 06, 2023

Themis Medicare posts Q2 FY24 PAT at Rs. 11.31 Cr

The company has reported total income of Rs. 107.22 crores during the period ended September 30, 2023


Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI
Digitisation | November 03, 2023

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists


Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs
News | November 03, 2023

Lyka Labs posts Q2 FY24 loss at Rs. 48.65 lakhs

Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023


Pfizer posts Q3 loss as Covid-19 revenues shrink
News | November 01, 2023

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion


Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biotech | October 31, 2023

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution


Alkem ‘Healthy Lungs' initiative aims to clear the air
News | October 31, 2023

Alkem ‘Healthy Lungs' initiative aims to clear the air

The initiative will focus on advocating for cleaner air


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
News | October 30, 2023

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months


USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
Drug Approval | October 26, 2023

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer


Nanoform grant global starmap AI license to AstraZeneca
Digitisation | October 25, 2023

Nanoform grant global starmap AI license to AstraZeneca

Nanoform will receive access to compound libraries and large data sets to undertake STARMAP screening